It all sounds very promising on the surface and CLDX does have a pretty small market cap. But, one still presumably has to be concerned about PFE pulling out of the partnership for the drug. Was that due strictly to changing business priorities at PFE or did it reflect some specific underlying concerns that PFE had with the drug (or some combination of the two)?
Market Data 
Markets 
AI
